RSS-Feed abonnieren
DOI: 10.1055/s-0031-1280652
Hepatic Artery Dissection in a Patient on Bevacizumab Resulting in Pseudoaneurysm Formation
Publikationsverlauf
Publikationsdatum:
16. Juni 2011 (online)
ABSTRACT
Interventional radiologists are frequently encountering patients with colorectal cancer that are being treated with bevacizumab. This therapeutic agent is associated with a potentially increased risk of adverse events when invasive procedures are performed while patients are on therapy. The current case report reviews a complication related to planning angiography for radioembolization with Yttrium-90 microspheres in an individual on bevacizumab and subsequent management of the patient.
KEYWORDS
Radioembolization - complications - bevacizumab - colorectal cancer
REFERENCES
- 1 Gordon C R, Rojavin Y, Patel M et al.. A review on bevacizumab and surgical wound healing: an important warning to all surgeons. Ann Plast Surg. 2009; 62 (6) 707-709
- 2 Kemeny M M. How many patients and how many complications does it take to decide if a drug is safe to use before surgery?. J Clin Oncol. 2009; 27 (11) 1917-1918, author reply 1918
- 3 Kesmodel S B, Ellis L M, Lin E et al.. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol. 2008; 26 (32) 5254-5260
- 4 Petrelli N J. Bevacizumab and postoperative complications after hepatic surgery for colorectal metastases. J Clin Oncol. 2009; 27 (11) 1917, author reply 1918
- 5 Scappaticci F A, Fehrenbacher L, Cartwright T et al.. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol. 2005; 91 (3) 173-180
- 6 Cheon E C, Small Jr W, Strouch M J et al.. The effects of bevacizumab on postoperative complications in patients undergoing colorectal and pancreatic cancer resection. J Surg Oncol. 2010; 102 (5) 539-542
- 7 Hurwitz H, Fehrenbacher L, Novotny W et al.. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350 (23) 2335-2342
- 8 Kabbinavar F F, Schulz J, McCleod M et al.. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol. 2005; 23 (16) 3697-3705
- 9 Erinjeri J P, Fong A J, Kemeny N E, Brown K T, Getrajdman G I, Solomon S B. Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer. 2011; 117 (6) 1296-1301
- 10 Brown D B, Cardella J F, Sacks D et al.. Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol. 2009; 20 (7, Suppl) 219-226
- 11 Ahn J, Trost D W, Mitty H A, Sos T A. Pseudoaneurysm formation after catheter dissection of the common hepatic artery: report of two cases. Am J Gastroenterol. 1997; 92 (4) 696-699
Daniel B BrownM.D.
Division of Interventional Radiology and the Kimmel Cancer Center, Thomas Jefferson University
132 South 10th Street, Suite 766, Philadelphia, PA 19107
eMail: daniel.brown@jefferson.edu